It starts in the gut. But the damage shows up in the liver.
An experimental compound called DT-109 appears to stop that cycle.
Researchers at Michigan Medicine say they have identified the mechanism. They published their findings in The Journal of Clinical Investigation. The results? It repairs the gut lining and reverses severe metabolic dysfunction-associated steatohepatitis, or MASH, in animal models.
Why does this matter? MASH affects about 7% of the global population. It isn’t just “fatty liver.” It progresses to cirrhosis. Liver cancer. Liver failure. Current treatments are sparse.
DT-109 offers a different approach. It targets the gut-liver axis directly.
The Ammonia Problem Driving Liver Damage
To fix MASH, you first need to understand the engine failure.
Eugene Chen, M.D., Ph.d., led the study. He notes that DT-109 targets a harmful pathway between the intestines and the liver.
The culprit is specific. Clostridium perfringens. A bacterium that grows rapidly in the guts of MASH patients. It produces ammonia.
Ammonia raises its game by attacking the intestinal wall. It damages the epithelial barrier. When that barrier weakens, things escape.
Harmful microbial products flow into the bloodstream. They travel to the liver. The immune system notices. CD8+ T cells activate excessively. Inflammation spikes. Liver health degrades.
Chen put it clearly: “We see clear evidence that DT-1109 protects the gut… reducing the systemic influx of harmfulicrobial products.”
Blocking the Bacterial Supply Chain
DT-109 interrupts that chain.
The team didn’t just guess. They tested the theory in mice and nonhuman primates—their biology mirrors human systems more closely.
The drug reduces levels of C. perfringens. Less bacteria means less ammonia produced in the intestines.
Lower ammonia allows the intestinal barrier to heal. Strength returns to the gut lining.
“Holes” seal shut.
Harmful substances can’t slip out as easily. They stay contained. The liver stops receiving constant toxic insults. Inflammation subsides.
This is key: DT-109 acts primarily in the gastrointestinal tract. Yet the effect ripples far beyond the stomach.
“This compound shows benefits… and has great potential as a treatment,” Chen said.
Jifeng Zhang, co-author, described it as connecting microbiota modulation with actual liver protection. By restoring barrier integrity, the drug limits systemic translocation of toxins.
Beyond Liver Health
Could this drug fix other conditions?
Possibly.
A weak gut barrier plays a role in many digestive disorders. The team suggests exploring DT-109 for inflammatory bowel disease (IBD) in the future.
Cardiovascular health is another target. Previous studies show the tripeptide reduces atherosclerosis plaques in nonhuman primates. It even prevents vascular calcification.
Heart disease and fatty liver often walk hand in hand. A single compound targeting the gut might offer protection for both organs simultaneously.
“The compound… can reduce the development of… plaques,” previous research indicates. If it works in animals, it should work in humans, presumably. But we need proof.
From Lab to Human Trials
Translation is the hard part.
Animal results are promising. Encouraging, even. But primates are not humans.
The next step is clinical trials. Safety and efficacy must be proven in people. Elliot Tapper, Academic Director of Hepatology, notes the excitement but remains grounded.
“What patients with MASH need is a fast and effective therapy… of course we are excited,” Tapper said.
They aren’t there yet. But the path is clearer than before.
Funding sources include Diapin Therapeutics, which has licensed the compound. Inventors on the team hold an interest in the company. Conflicts exist, standard for this stage of development.
Still, the science holds together. The link between gut bacteria, ammonia, and liver failure is real. DT-109 severs that link.
Will it work in humans? The jury is still out. But for those waiting for options, this feels like a step in the right direction. The gut repair is just the beginning.
